11th World Affordable Medicine Congress

11th World Affordable Medicine Congress 7 - 8 February 2017, Barcelona, Spain.
The Annual World Affordable Medicine Congress comes to Barcelona, this is the newly rebranded World Generic Medicines Congress and Biosimilar Drug Development World. For 11 years, the biggest and best in the industry. Through a series of interactives presentation, speed networking and stream sessions, the congress will provide fresh insights into future market trends, innovative commercial strategies and opportunities for growth for affordable medicines.

Don't miss out the opportunity to share your experience and network with senior and board level executives working in generic and biosimilar organisations.

Don't miss your chance to hear from:

  • Klaus Martin, Chief Scientific Officer, Polpharma Biologics
  • Matthew Turner, Global Medical Director Biosimilars, Merck
  • Bernd Liedert, Sr.Clinical Program Leader Biosimilars, Boehringer Ingelheim
  • Isabel Afonso, Head of Global Commercial Strategy and member of the Sandoz Executive Committee, Sandoz
  • Steinar Madsen, Medical Director, Norwegian Medicines Agency
  • Adrian Thomas, Vice President of Health Economics & Market Access, Janssen North America

Download the brochure now to see who's speaking.

World Pharma News readers can benefit from an exclusive 10% discount. Quote discount code CGNN

For further information, please visit:
http://www.healthnetworkcommunications.com/conference/affordable-medicines/

About World Affordable Medicine Congress
The World Affordable Medicine Congress Europe brings together two world class events - World Generic Medicines Congress and Biosimilar Drug Development World - that have been central to the industry’s business and networking needs for over 10 years. Over 2000 business leaders participants have benefited from this series since 2007.

The event unites senior executives from the generic and biosimilar industry to provide fresh insights into future market trends, innovative commercial strategies and opportunities for growth for affordable medicines.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]